IGC
Price
$0.37
Change
+$0.01 (+2.78%)
Updated
Aug 15 closing price
Capitalization
31.03M
Earnings call today
PRME
Price
$3.57
Change
-$0.07 (-1.92%)
Updated
Aug 15 closing price
Capitalization
636.44M
75 days until earnings call
Interact to see
Advertisement

IGC vs PRME

Header iconIGC vs PRME Comparison
Open Charts IGC vs PRMEBanner chart's image
IGC Pharma
Price$0.37
Change+$0.01 (+2.78%)
Volume$392.52K
Capitalization31.03M
Prime Medicine
Price$3.57
Change-$0.07 (-1.92%)
Volume$3.67M
Capitalization636.44M
IGC vs PRME Comparison Chart in %
Loading...
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IGC vs. PRME commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGC is a Hold and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (IGC: $0.37 vs. PRME: $3.57)
Brand notoriety: IGC and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IGC: 11% vs. PRME: 77%
Market capitalization -- IGC: $31.03M vs. PRME: $636.44M
IGC [@Biotechnology] is valued at $31.03M. PRME’s [@Biotechnology] market capitalization is $636.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IGC’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • IGC’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, IGC is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IGC’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • IGC’s TA Score: 4 bullish, 4 bearish.
  • PRME’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, IGC is a better buy in the short-term than PRME.

Price Growth

IGC (@Biotechnology) experienced а +8.95% price change this week, while PRME (@Biotechnology) price change was -5.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

IGC is expected to report earnings on Aug 18, 2025.

PRME is expected to report earnings on Oct 31, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($636M) has a higher market cap than IGC($31M). PRME YTD gains are higher at: 22.260 vs. IGC (10.089). IGC has higher annual earnings (EBITDA): -7.58M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. IGC (470K). IGC has less debt than PRME: IGC (270K) vs PRME (121M). PRME has higher revenues than IGC: PRME (3.85M) vs IGC (1.24M).
IGCPRMEIGC / PRME
Capitalization31M636M5%
EBITDA-7.58M-200M4%
Gain YTD10.08922.26045%
P/E RatioN/AN/A-
Revenue1.24M3.85M32%
Total Cash470K144M0%
Total Debt270K121M0%
FUNDAMENTALS RATINGS
IGC vs PRME: Fundamental Ratings
IGC
PRME
OUTLOOK RATING
1..100
5059
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
4539
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IGC's Valuation (47) in the Biotechnology industry is in the same range as PRME (65) in the null industry. This means that IGC’s stock grew similarly to PRME’s over the last 12 months.

IGC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that IGC’s stock grew similarly to PRME’s over the last 12 months.

IGC's SMR Rating (99) in the Biotechnology industry is in the same range as PRME (99) in the null industry. This means that IGC’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (39) in the null industry is in the same range as IGC (45) in the Biotechnology industry. This means that PRME’s stock grew similarly to IGC’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as IGC (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to IGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IGCPRME
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 4 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 28 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
82%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BTG3.900.07
+1.83%
B2Gold Corp
COSO20.04N/A
-0.02%
CoastalSouth Bancshares Inc
KTCC2.78-0.01
-0.36%
Key Tronic Corp
NMFC10.30-0.06
-0.58%
New Mountain Finance Corp
CTAS216.55-4.36
-1.97%
Cintas Corp

IGC and

Correlation & Price change

A.I.dvisor indicates that over the last year, IGC has been loosely correlated with MRNA. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if IGC jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
+2.75%
MRNA - IGC
33%
Loosely correlated
+4.98%
KZR - IGC
33%
Poorly correlated
-0.25%
ARTL - IGC
30%
Poorly correlated
-0.69%
PRME - IGC
29%
Poorly correlated
-1.92%
RYTM - IGC
29%
Poorly correlated
+1.17%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-1.92%
CRSP - PRME
58%
Loosely correlated
+1.55%
BEAM - PRME
54%
Loosely correlated
+1.08%
RXRX - PRME
53%
Loosely correlated
+2.30%
CRBU - PRME
48%
Loosely correlated
-1.00%
EDIT - PRME
47%
Loosely correlated
+2.36%
More